(AKBA) Akebia Ther - Ratings and Ratios

Akebia Therapeutics, Inc. (NASDAQ:AKBA) is a biopharmaceutical company specializing in the development and commercialization of innovative therapies for patients with kidney diseases. The companys lead investigational product, Vafseo (vadadustat), is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor currently in Phase III trials for treating anemia associated with chronic kidney disease (CKD) in both dialysis-dependent and non-dialysis patients. Akebia also markets Auryxia, a ferric citrate indicated for controlling serum phosphorus levels in dialysis-dependent CKD patients and treating iron deficiency anemia in non-dialysis CKD patients. The companys pipeline includes AKB-9090, a compound targeting critical-care indications, and AKB-10108, which focuses on conditions related to premature birth. Collaborations include a partnership with Mitsubishi Tanabe Pharma Corporation for vadadustat development and commercialization in Japan and other Asian markets, as well as a research and license agreement with Janssen Pharmaceutica NV for hypoxia-inducible factor prolyl hydroxylase-targeted therapies worldwide. Founded in 2007 and headquartered in Cambridge, Massachusetts, Akebia is committed to advancing treatments for kidney disease and related conditions. Web URL: https://www.akebia.com

Ticker Symbol: AKBA Exchange: NASDAQ Type: common stock Country Origin: United States GICS Sub Industry: Biotechnology

Support: 1.4

Average Volume 20d: 1,969,439 Last Price: 1.83 SMA 20: 2.04 SMA 50: 2.01 SMA 200: 1.56 ATR: 0.09

Market Cap: $392.73M USD P/E: 0.00 P/E Forward: 0.00 P/B: 4.12 P/S: 2.31 RoE: 91.25

3-Month Forecast: Based on the technical and fundamental data, Akebia Therapeutics (AKBA) is expected to face headwinds in the near term. The stock is trading below its SMA 20 and SMA 50, indicating bearish momentum. The high price-to-book ratio of 4.12 suggests elevated valuations relative to book value, which could limit upside potential. However, the positive return on equity (RoE) of 91.25% indicates efficient profitability from equity. The stock may experience volatility within a narrow range, bounded by the identified support level of 1.4. A potential stabilization or recovery could occur if the company reports positive clinical trial data or strengthens its pipeline.